Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337-2346.

doi:10.1182/blood.2022015436

On page 2337, an author’s surname is misspelled. “Reuven Shore” should read “Reuven Schore.” The error has been corrected in the online version of the article.

2022

Sign in via your Institution

Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337-2346.

Cited By

Email alerts

ASH Publications

American Society of Hematology

Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337-2346.

This feature is available to Subscribers Only

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only